B Cell Depletion in IgG4-Related Disease



As IgG4-related disease (IgG4-RD) emerged and then began to come into sharper clinical focus during the first decade of the new century, those who have studied the disease have been privileged to appreciate many “Eureka” moments. One such moment was the observation of the substantial effect of B cell depletion on the clinical features and laboratory manifestations on IgG4-RD. Investigations of the use of this treatment strategy and studies of its mechanistic effects have led to important observations and are likely to yield important additional information about the nature of this disease.


Plasma Cell Parotid Gland Lacrimal Gland Cell Depletion IgG4 Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kamisawa T, Shimosegawa T, Okazaki K, et al. Gut. 2009;58:1504–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Deshpande V, Zen Y, Ferry JA, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25(9): 1181–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Isaacs JD, Cohen SB, Emery P et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;329–36.Google Scholar
  4. 4.
    Stone JH, Merkel PA, Spiera R, et al. Rituximab compared with cyclophosphamide for remission induction in ANCA-associated vasculitis. N Engl J Med. 2010;363:221–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Ahmed AR, Spigelman X, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Beck Jr LH, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009;361:11–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Stone JH. IgG4: a tantalizing connection between membranous glomerulonephritis and systemic disease. Kidney Int. 2012;83: 348–50.CrossRefGoogle Scholar
  8. 8.
    Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am J Gastroenterol. 2003;98:2811–2.PubMedCrossRefGoogle Scholar
  9. 9.
    Khosroshahi A, Bloch DB, Deshpande V, Stone JH. Rituximab therapy leads to swift decline of serum IgG4 levels and prompt clinical improvement in IgG4-related disease. Arthritis Rheum. 2010;62:1755–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Khosroshahi A, Carruthers MD, Deshpande V, Leb L, Reed J, Stone JH. Cutaneous IgG4-related disease. Am J Med. 2011;124:e7–8.PubMedCrossRefGoogle Scholar
  11. 11.
    Khosroshahi A, Carruthers MD, Deshpande V, et al. Rituximab for the treatment of IgG4-related systemic disease: lessons from a series of ten consecutive cases. Medicine (Baltimore). 2012;91:57–66.CrossRefGoogle Scholar
  12. 12.
    Carruthers MN, Stone JH, Deshpande V, Khosroshahi A. Development of an IgG4-RD responder index. Int J Rheumatol. 2012;2012:259408.PubMedGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Rheumatology Clinic/Yawkey 2Massachusetts General HospitalBostonUSA

Personalised recommendations